Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
EyePoint, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
EYPT
Nasdaq
2834
eyepoint.bio
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for EyePoint, Inc.
EyePoint Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
- Nov 12th, 2026 11:17 am
EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates
- Nov 12th, 2026 5:35 am
EyePoint: Q3 Earnings Snapshot
- Nov 12th, 2026 5:32 am
EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments
- Nov 12th, 2026 5:00 am
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
- Nov 6th, 2026 5:00 am
EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
- Nov 5th, 2026 5:00 am
Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Nov 2nd, 2026 7:00 am
EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?
- Oct 28th, 2026 7:00 am
EyePoint (EYPT) Stock Sees Fair Value Cut After Duravyu Trial Setbacks
- Oct 20th, 2026 8:15 pm
EyePoint halves workforce and ends Phase III trial early after endpoint miss
- Oct 20th, 2026 5:37 am
Why Did EYPT, CRWV, EOSE Stocks Tumble To 52-Week Lows Today?
- Oct 19th, 2026 8:39 pm
EYPT Stock Layoffs: What to Know About the Latest EyePoint Job Cuts
- Oct 19th, 2026 2:58 pm
Top Midday Decliners
- Oct 19th, 2026 12:47 pm
EyePoint Drug Trial Flop Crashes Stock. Can a Strategy Shift Save It?
- Oct 19th, 2026 10:57 am
BC-Most Active Stocks
- Oct 19th, 2026 8:30 am
EyePoint crashes as pivotal wet AMD trial fails, prompting 53% workforce cut
- Oct 19th, 2026 7:58 am
EyePoint Announces 53% Workforce Reduction Following Phase 3 DURAVYU Trial Results
- Oct 19th, 2026 6:47 am
EyePoint Pharmaceuticals to Cut 53% of Workforce After Eye Disease Drug Trial Setback
- Oct 19th, 2026 6:08 am
Scroll